The term “primary cutaneous small/medium CD4+ T-cell lymphoma” was changed to “primary cutaneous small/medium CD4+ lymphoproliferative disorder” due to its indolent clinical behavior and uncertain malignant potential. The gene discussed is CD4; the disease is T-cell non-Hodgkin lymphoma.